Press Release: Dupixent approved in the US as the first-ever
WEB1 hour ago · The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Dupixent is the first biologic medicine approved in the US to treat these patients.
DUPIXENT® (dupilumab) for Adults with Inadequately Controlled COPD
WEBA Breakthrough Treatment FOR COPD is Here. DUPIXENT is an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and a high number of blood eosinophils (a type of white blood cell that may contribute to your COPD). Not actual patients. SHARE THE NEWS: DUPIXENT IS APPROVED FOR COPD!
Dupixent approved in the US as the first-ever biologic medicine …
WEB3 days ago · The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Dupixent is the first biologic medicine approved in the US to treat these patients.
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB2 days ago · The FDA has expanded the label of Regeneron and Sanofi's Dupixent to treat COPD. Dupixent becomes the first biologic for COPD patients in the U.S.
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEB3 days ago · FDA, after delay, clears Regeneron and Sanofi drug for COPD Dupixent is the first biologic medicine approved in the U.S. for the common lung condition, though competitors from GSK, AstraZeneca and Roche could follow.
Press Release: Dupixent approved in China as the first-ever
WEB1 hour ago · Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved lung function, and also improved health-related quality of life COPD is the most prevalent chronic ...
Dupilumab Becomes First Biologic Approved in the US as Targeted …
WEB3 days ago · September 27, 2024. By Grace Halsey. News. Article. Dupilumab represents the first new treatment approach for uncontrolled COPD in more than a decade and reduced disease exacerbations by 34% in clinical trials. Sanofi and Regeneron Pharmaceuticals announced today that the US FDA has approved the biologic dupilumab (Dupixent) as …
Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD …
WEBMay 20, 2024 · NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation. Data support the potential of …
Dupilumab for COPD with Type 2 Inflammation Indicated by …
WEBMay 21, 2023 · In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts. Dupilumab, a fully...
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results …
WEBMay 21, 2023 · Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo.